Chronic Wounds

Chronic wounds remain a significant healthcare challenge, particularly due to the increasing number of affected patients and the lack of sufficiently effective treatment options. The therapeutic effects of MSCs (mesenchymal stem/stromal cells) are primarily mediated through the secretion of various bioactive molecules that stimulate local cellular responses and modulate the harsh microenvironment characteristic of chronic wounds.
Establish cooperation
Clinical Rationale for MSC Therapy in Chronic Wounds

Chronic, non-healing wounds remain a major clinical and economic burden despite advances in dressings, growth factors, and skin substitutes. These wounds are typically characterized by persistent inflammation, impaired angiogenesis, and defective extracellular matrix (ECM) remodeling.

Mesenchymal stem cells (MSCs) are emerging as a promising adjunct therapy because they target multiple pathological mechanisms simultaneously through immunomodulation and paracrine signaling rather than simply replacing lost cells.

Preclinical and Clinical Evidence
Accelerated Healing and Tissue Regeneration

Across preclinical models and human studies, MSC treatment has been shown to:

  • Accelerate wound closure
  • Enhance granulation tissue formation
  • Promote re-epithelialization
  • Increase blood vessel density
Adipose-Derived MSCs (AD-MSCs)

AD-MSCs are particularly attractive due to their abundance, ease of harvest, strong ex vivo expansion, and secretion of pro-angiogenic factors. They have been successfully applied in:

  • Diabetic foot ulcers
  • Venous and hypertensive ulcers
  • Peripheral arterial disease–related wounds
  • Post-surgical defects

Clinical outcomes include faster healing, reduced pain, and improved cosmetic results when combined with optimal local wound care.

Other MSC Sources

MSCs derived from bone marrow, placenta, and umbilical cord have also demonstrated meaningful improvements in closure rates and quality of healing in lower extremity ulcers, pressure sores, and radiation burns, with an acceptable short-term safety profile and few serious adverse events.

Best Practices for MSC Therapy

“Good practice” principles emphasize that MSC therapy should always complement meticulous standard care, including:

  • Wound bed preparation and debridement
  • Infection and biofilm control
  • Off-loading or compression as appropriate
  • Optimization of perfusion and systemic factors, such as glycemic control
Local Delivery Methods

Local delivery—via perilesional injections or topical application in fibrin sprays, hydrogels, or dermal substitutes—is more effective than systemic administration, improving cell engraftment and retention. Combining AD-MSCs with platelet-rich plasma, fat grafts, or biomaterial scaffolds further enhances tissue volume restoration, vascularity, and closure durability without major side effects.

Mechanisms of Action

MSCs act primarily through paracrine signaling:

  • Release of cytokines, growth factors, and extracellular vesicles (EVs)
  • Suppression of excessive inflammation
  • Polarization of macrophages toward a pro-healing phenotype
  • Stimulation of fibroblast migration and ECM deposition
  • Promotion of angiogenesis and keratinocyte proliferation
Cell-Free Approaches: MSC Secretome and Extracellular Vesicles

MSC-derived secretome or EVs retain many regenerative and immunomodulatory benefits while reducing risks such as tumorigenicity, embolism, and long-term engraftment.

Preclinical studies show that small EVs:

  • Improve wound closure, collagen deposition, and neovascularization
  • Promote regeneration of complex skin structures (vessels, nerves, hair follicles)
  • Limit scarring through angiogenic and antifibrotic pathway modulation

Subcutaneous delivery and adipose-derived sources appear especially effective.

Challenges and Future Directions

Despite promising results, clinical evidence is limited by:

  • Small sample sizes
  • Heterogeneous cell preparations and dosing
  • Variable outcome measures

Key elements of responsible practice include:

  • Rigorous cell characterization and quality control
  • Standardized culture and storage protocols
  • Careful patient selection (e.g., excluding active malignancy or uncontrolled infection)
  • Delivery within controlled trials or specialized centers

Emerging strategies such as gene modification, hypoxic preconditioning, and advanced biomaterial scaffolds aim to improve MSC survival, homing, and potency, with early data suggesting enhanced tissue regeneration and reduced scarring.

Summary

MSC-based therapies—particularly AD-MSCs and their extracellular vesicles—represent a safe and promising adjunct for chronic wound management. They can accelerate wound closure, improve neovascularization, reduce pain, and potentially limit scarring when integrated with best-practice wound care and optimized local administration strategies. Large, well-designed randomized controlled trials and standardized protocols are still essential before MSC therapy can become a routine, evidence-based treatment.

Therapeutic area:
Chronic Wounds

REFERENCE:

Huang, Y., Gou, M., Da, L., Zhang, W., & Xie, H. (2020). Mesenchymal Stem Cells for Chronic Wound Healing: Current Status of Preclinical and Clinical Studies. Tissue Engineering Part B: Reviews, 26, 555–570. https://doi.org/10.1089/ten.teb.2019.0351

Farabi, B., Roster, K., Hirani, R., Tepper, K., Atak, M., & Safai, B. (2024). The Efficacy of Stem Cells in Wound Healing: A Systematic Review. International Journal of Molecular Sciences, 25. https://doi.org/10.3390/ijms25053006

Gentile, P., & Garcovich, S. (2021). Systematic Review: Adipose-Derived Mesenchymal Stem Cells, Platelet-Rich Plasma and Biomaterials as New Regenerative Strategies in Chronic Skin Wounds and Soft Tissue Defects. International Journal of Molecular Sciences, 22. https://doi.org/10.3390/ijms22041538

Otero-Viñas, M., & Falanga, V. (2016). Mesenchymal Stem Cells in Chronic Wounds: The Spectrum from Basic to Advanced Therapy. Advances in Wound Care, 5, 149–163. https://doi.org/10.1089/wound.2015.0627

Zhu, Y., Yang, H., Xue, Z., Tang, H., Chen, X., & Liao, Y. (2025). Mesenchymal stem cells-derived small extracellular vesicles and apoptotic extracellular vesicles for wound healing and skin regeneration: a systematic review and meta-analysis of preclinical studies. Journal of Translational Medicine, 23. https://doi.org/10.1186/s12967-024-05744-0

Ding, J., Chen, M., Wu, L., Shu, G., Fang, S., Li, Z., Chu, X., Li, X., Wang, Z., & Ji, J. (2023). Mesenchymal stem cell-derived extracellular vesicles in skin wound healing: roles, opportunities and challenges. Military Medical Research, 10. https://doi.org/10.1186/s40779-023-00472-w

Gao, M., Guo, H., Dong, X., Wang, Z., Yang, Z., Shang, Q., & Wang, Q. (2024). Regulation of inflammation during wound healing: the function of mesenchymal stem cells and strategies for therapeutic enhancement. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1345779

Razavi, Z., Sharafshadehi, S., Yousefi, M., Javaheri, F., Barghani, M., Afkhami, H., & Heidari, F. (2025). Application of novel strategies in chronic wound management with focusing on pressure ulcers: new perspective. Archives of Dermatological Research, 317. https://doi.org/10.1007/s00403-024-03790-8

Spence, S., & Gallicchio, V. (2022). Mesenchymal Stem Cell Therapy For Chronic Wound Healing. Journal of Stem Cell Research. https://doi.org/10.52793/jscr.2022.3(1)-01

Guillamat-Prats, R. (2021). The Role of MSC in Wound Healing, Scarring and Regeneration. Cells, 10. https://doi.org/10.3390/cells10071729

Nuschke, A. (2014). Activity of mesenchymal stem cells in therapies for chronic skin wound healing. Organogenesis, 10, 29–37. https://doi.org/10.4161/org.27405

Fakouri, A., Razavi, Z., Mohammed, A., Hussein, A., Afkhami, H., & Hooshiar, M. (2024). Applications of mesenchymal stem cell-exosome components in wound infection healing: new insights. Burns & Trauma, 12. https://doi.org/10.1093/burnst/tkae021

Kosaric, N., Kiwanuka, H., & Gurtner, G. (2019). Stem cell therapies for wound healing. Expert Opinion on Biological Therapy, 19, 575–585. https://doi.org/10.1080/14712598.2019.1596257

Lee, D., Ayoub, N., & Agrawal, D. (2016). Mesenchymal stem cells and cutaneous wound healing: novel methods to increase cell delivery and therapeutic efficacy. Stem Cell Research & Therapy, 7. https://doi.org/10.1186/s13287-016-0303-6

, H., Siu, W., & Leung, P. (2023). The Potential of MSC-Based Cell-Free Therapy in Wound Healing—A Thorough Literature Review. International Journal of Molecular Sciences, 24. https://doi.org/10.3390/ijms24119356

Wang, D., Chen, A., Fang, Y., , C., Lu, Y., Zhou, C., Liu, Q., & Jiang, B. (2025). Engineering strategies to enhance the research progress of mesenchymal stem cells in wound healing. Stem Cell Research & Therapy, 16. https://doi.org/10.1186/s13287-025-04471-7

Margiana, R., Markov, A., Zekiy, A., Hamza, M., Al-Dabbagh, K., Al-Zubaidi, S., Hameed, N., Ahmad, I., Sivaraman, R., Kzar, H., Al-Gazally, M., Mustafa, Y., & Siahmansouri, H. (2022). Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review. Stem Cell Research & Therapy, 13. https://doi.org/10.1186/s13287-022-03054-0

Wu, S., Sun, S., Fu, W., Yang, Z., Yao, H., & Zhang, Z. (2024). The Role and Prospects of Mesenchymal Stem Cells in Skin Repair and Regeneration. Biomedicines, 12. https://doi.org/10.3390/biomedicines12040743

Raghuram, A., Yu, R., Lo, A., Sung, C., Bircan, M., Thompson, H., & Wong, A. (2020). Role of stem cell therapies in treating chronic wounds: A systematic review. World Journal of Stem Cells, 12, 659–675. https://doi.org/10.4252/wjsc.v12.i7.659

Read more
crossmenu